ANDREW GENAW: Open Payments
NPI 1285898528 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 28 payments from 14 companies in 2025. Trend: 2023 $207 · 2024 $608 · 2025 $597
Food & beverage: $597
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $97 |
| UCB, Inc. | 3 | $67 |
| ABBVIE INC. | 3 | $63 |
| Lilly USA, LLC | 3 | $58 |
| PFIZER INC. | 2 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Novo Nordisk Inc | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
Products named: INGREZZA, ELIQUIS, Briviact, REXULTI, ZENPEP, Ozempic, CAPLYTA, MOUNJARO.
Industry payments across WI — which companies pay providers there.
